3,812 Photos and videos
#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: gsk.to/4eoSdHf
274
#News for #investors and #media:
We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: gsk.to/4ooHOjy
3
4
8
1,539
#News for #investors and #media:
We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: gsk.to/4dQBSLg.
1
449
Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management.
At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.
1
2
712
News for #Investors and #Media
Explore the key highlights from our Q1 2026 results announcement ⤵️
Find out more: gsk.to/4uelV7Y $GSK
1
1
9
1,752
News for #Investors and #Media
Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026.
Find out more: gsk.to/3OA31JU
$GSK #Q1Results
2
3
11
1,817
News for #Investors and #Media: Today, we announced the US Food and Drug Administration accepted our application for a potential first-in-class treatment for chronic hepatitis B. Learn more: gsk.to/4darMFN
1
2
497
Current treatments for #cUTIs caused by drug-resistant organisms often require hospitalization. The lack of oral treatments can result in extended hospital stays, ultimately having a negative impact on patients’ quality of life.
We remain focused to address the growing issue of antimicrobial resistance.
#ESCMIDGlobal2026
1
384
#News for #Investors and #Media: At #SGO2026, we presented new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/47V3hJO.
1
586
Our partnership with the lupus community has always been fueled by a clear purpose: to improve the outcomes for people living with lupus.
This dedication to advancing breakthroughs continues to drive our work as we look ahead to the future of lupus care.
#Lupus #AheadTogether
2
1
4
361
We‘ve topped the Access to Medicine Index's 2026 Antimicrobial Resistance Benchmark, reflecting our continuous focus on delivering innovative antibiotic medicines and vaccines for patients with significant unmet medical need.
Check out our #AMR podcast: gsk.to/4rj3UUt
1
606
Our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.
Take a look at the highlights ⤵️
🔗 Investors and media can read more: gsk.to/4ubX9pQ
4
4
10
2,227
We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more. If you can’t attend, you can learn more about our work here: gsk.me/4tYOfvR 🫁
1
1
4
486
Explore the key highlights from our Q4 and full year 2025 results announcement ⤵️
More information for media and investors: gsk.to/4a2WXQw $GSK
2
2
8
1,758
Watch our CEO Luke Miels as he shares our strong 2025 performance and reaffirms our long-term outlooks.
More insights and information for media and investors: gsk.to/4ti5YOs $GSK #FYResults
4
1
12
1,713
#News for #Media: Meet the Linked by Lupus: Optimal Care Initiative grant awardees; orgs working to improve early diagnosis, expand access to treatment, and strengthen patient-provider communications for those impacted by #lupus.
Read more about the grant and awardees: gsk.to/3LRfTd4
1
1
3
613
#News for #investors and #media: We’ve announced an agreement to acquire RAPT Therapeutics.
Find out more: gsk.to/3NuAT9Z
4
4
13
8,850
We're leaving #JPM2026 inspired and confident in our R&D momentum & future pipeline impact. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together.
#AheadTogether
1
573
We’re excited to announce Court Horncastle's selection as a Life Sciences Voice Top Industry Leader, a testament to his 30 years leading teams and redefining the future of specialty medicine to help get ahead of disease. Congratulations, Court!
#AheadTogether #GSKProud
1
428
Yesterday at #JPM2026: our CSO Tony Wood joined Endpoint News to share how our focused R&D approach – driven by science, advanced tech, and strategic partnerships – is accelerating pipeline momentum and our ambition to transform health.
🔗 Learn more: gsk.to/4qRrt6X
1
554